Startup developing novel treatment for life-threatening lung condition

July 11, 2018, Purdue University
Spirrow Therapeutics, a Purdue University-related startup, is developing a novel treatment for a life-threatening lung condition known as acute respiratory distress syndrome, or ARDS. The treatment uses a nanoparticle to mimic the behavior of a natural surfactant in the lungs to work within the lungs’ processes for inflation and oxygenation. Credit: Purdue University

A Purdue University-affiliated startup developing a novel treatment for a life-threatening lung condition known as acute respiratory distress syndrome, or ARDS, is taking part in a prestigious startup accelerator program where about $2 million in funding is available.

Spirrow Therapeutics (formerly Spiro Therapeutics) was selected to be a finalist from a pool of 1,600 applicants to take part in MassChallenge, the Boston-based startup accelerator that offers work space, an opportunity to connect with physicians and mentors and funding opportunities. The program will help as the researchers continue their work to create a novel nanopolymer surfactant that supplements inflation and blood oxygenation in ARDS patients.

"This is going to open a lot of opportunities for us to talk to experts," said Davis Arick, a co-founder of Spirrow Therapeutics who recently graduated from Purdue with a chemical engineering degree. "There are a lot of pulmonologists in the Boston area who work with ARDS regularly. We want to assemble an advisory board that can help us as we develop clinical studies."

Arick co-founded Spirrow Therapeutics with Kyle Kim, who earned a chemical engineering doctorate from Purdue, and You-Yeon Won, a Purdue chemical engineering professor. Originally interested in neonatal lung function, the researchers turned their attention to ARDS after discovering a greater need there.

The United States has about 220,000 cases a year of ARDS, which deactivates the naturally occurring lung surfactant in patients. That causes a decreased ability to inflate the tiny air sacs in lungs called alveoli. When inadequately inflated, the alveoli cannot totally oxygenate a patient's blood stream, which can lead to organ failure and other health problems.

ARDS can be caused by pneumonia, septic shock, trauma, inhaling chemicals or other trauma. About 40 percent of people with ARDS die.

"So far, no ARDS treatments have improved mortality rates or long-term effects in ARDS patients," Arick said. "These patients don't have a great outlook for survival because there are not many treatments available. Our hope is to achieve this improvement by engineering a nanoparticle that forms a barrier in the alveoli and allows inflation, despite the deactivation mechanism's presence."

Credit: Purdue University

ARDS is currently treated through ventilation and a process known as extracorporeal membrane oxygenation, or ECMO.

"Over time, patients have less and less positive effects from these treatments because they force air into the lungs and overinflate them," Arick said.

Spirrow Therapeutics' treatment mimics the behavior of the natural surfactant in the lungs to work within the lungs' processes for inflation and oxygenation. The researchers also believe it is immune to the deactivation effect of ARDS. They say they are not trying to cure ARDS but are providing a way to help until the body begins producing the natural surfactant again and begins using it correctly.

Arick said the MassChallenge program, which began on June 25 and runs through Oct. 17, is somewhat similar to Purdue's Burton D. Morgan Business Model Competition, which Spirrow Therapeutics won in March to capture the $25,000 first prize. He said just being one of the finalists will help the company.

"The funds that are available at MassChallenge are great, but the connections are priceless," said Arick, a veteran of the entrepreneurial process.

Arick's introduction to the Purdue entrepreneurial ecosystem began at a young age. He won first place in a high school competition at the Purdue Foundry, which clinched his decision to attend Purdue. While at the university, he also took part in Purdue's Certificate in Entrepreneurship and Innovation Program.

"It was meaningful to have exposure to entrepreneurial programs while pursuing my engineering degree," he said. "Purdue is very progressive in how they teach business planning. Purdue is really good about this new movement to get out of the building and go talk to people to figure out who your customer is."

In the short term, Spirrow Therapeutics will focus on testing in preclinical trials, networking with physicians and advancing their business through MassChallenge. Following, the startup plans to begin the Food and Drug Administration approval process with the plan to eventually work with a pharmaceutical company to bring its nanopolymer surfactant to market.

Explore further: 60-day mortality not significantly lower with ECMO in ARDS

Related Stories

60-day mortality not significantly lower with ECMO in ARDS

May 25, 2018
(HealthDay)—For patients with very severe acute respiratory distress syndrome (ARDS), 60-day mortality is not significantly lower with venovenous extracorporeal membrane oxygenation (ECMO) than with continued conventional ...

Synthetic surfactant could ease breathing for patients with lung disease and injury

July 9, 2018
Human lungs are coated with a substance called surfactant which allows us to breathe easily. When lung surfactant is missing or depleted, which can happen with premature birth or lung injury, breathing becomes difficult. ...

Lung therapy hope for critical illness

May 8, 2017
Scientists have pinpointed a chemical signal that worsens inflammation linked to a life-threatening lung condition.

Risk of mortality linked to interstitial lung abnormalities

May 15, 2016
New research uncovering a link between Interstitial Lung Abnormalities (ILA) and an increased risk of in-hospital mortality was shared at the ATS 2016 International Conference.

Putting lungs under less stress

June 5, 2018
The numbers are grim: Of the 200,000 Americans diagnosed with Acute Respiratory Distress Syndrome (ARDS) each year, 30 to 50 percent will die. But, clinical researchers at the University of Missouri School of Medicine's division ...

International panel updates definition of acute respiratory distress syndrome

May 21, 2012
Gordon D. Rubenfeld, M.D., of the Sunnybrook Health Sciences Center, Toronto, Canada, and colleagues with the ARDS (acute respiratory distress syndrome) Definition Task Force, developed a new definition of ARDS (the Berlin ...

Recommended for you

Study identifies stem cell that gives rise to new bone and cartilage in humans

September 20, 2018
A decade-long effort led by Stanford University School of Medicine scientists has been rewarded with the identification of the human skeletal stem cell.

Scientists grow human esophagus in lab

September 20, 2018
Scientists working to bioengineer the entire human gastrointestinal system in a laboratory now report using pluripotent stem cells to grow human esophageal organoids.

Researchers identify human skeletal stem cells

September 20, 2018
Human skeletal stem cells that become bone, cartilage, or stroma cells have been isolated from fetal and adult bones. This is the first time that skeletal stem cells, which had been observed in rodent models, have been identified ...

A new app enables a smartphone to ID bacteria in just one hour

September 20, 2018
In a potential game changer for the health care industry, a new cell phone app and lab kit now allow a smartphone to identify bacteria from patients anywhere in the world. With the new app, doctors will be able to diagnose ...

Synthetic sandalwood found to prolong human hair growth

September 19, 2018
A team of researchers led by Ralf Paus of the University of Manchester has found that applying sandalwood to the scalp can prolong human hair growth. In their paper published in the journal Nature Communications, the group ...

Zombie cells found in brains of mice prior to cognitive loss

September 19, 2018
Zombie cells are the ones that can't die but are equally unable to perform the functions of a normal cell. These zombie, or senescent, cells are implicated in a number of age-related diseases. And with a new letter in Nature, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.